Literature DB >> 7519206

Developmental regulation of the TCR zeta-chain. Differential expression and tyrosine phosphorylation of the TCR zeta-chain in resting immature and mature T lymphocytes.

M M Rozdzial1, R T Kubo, S L Turner, T H Finkel.   

Abstract

The zeta subunit of the TCR complex targets receptor surface expression, is phosphorylated on tyrosine residues upon T cell activation, and is implicated in signal transduction after TCR ligation. Here we show that, although intrathymic expression of the murine TCR-associated zeta-chain relative to the other chains of the Ag receptor complex remains unchanged during early thymocyte development, there is a doubling of TCR-associated zeta-chain surface expression upon thymocyte maturation. The ratio of tyrosine-phosphorylated relative to nonphosphorylated TCR-associated zeta-chain also changes with thymocyte development. This ratio was quantified after the purification and detergent extraction of receptor complexes from freshly isolated immature or mature thymocytes. Immunoprecipitation of the zeta-chain released from the complex allowed for the isolation of the tyrosine-phosphorylated and nonphosphorylated forms of TCR-associated zeta-chain. Intracellular free zeta-chain was characterized by immunoprecipitation after clearing the cell lysate of intact TCR complexes. Densitometric analysis of immunoblots indicated that surface phosphorylated zeta-chain is more abundant in immature relative to mature T cell populations, whereas the inverse is true of intracellular phosphorylated zeta-chain. Surface phosphorylated zeta-chain also migrated at a higher m.w. than its cytoplasmic counterpart, suggesting that it is more highly modified on some or all of its available tyrosines. These findings demonstrate that the stoichiometry and post-translational modification of the TCR complex are regulated, in vivo, and may determine the functional maturation of T cell signaling, selection, and activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519206

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  A role for CD8 in the developmental tuning of antigen recognition and CD3 conformational change.

Authors:  Diana Gil; Adam G Schrum; Mark A Daniels; Ed Palmer
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

2.  Development and function of T cells in T cell antigen receptor/CD3 zeta knockout mice reconstituted with Fc epsilon RI gamma.

Authors:  C P Liu; W J Lin; M Huang; J W Kappler; P Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  Physical and functional bivalency observed among TCR/CD3 complexes isolated from primary T cells.

Authors:  Adam G Schrum; Diana Gil; Laurence A Turka; Ed Palmer
Journal:  J Immunol       Date:  2011-06-10       Impact factor: 5.422

4.  Signaling efficiency of the T cell receptor controlled by a single amino acid in the beta chain constant region.

Authors:  B T Bäckström; B T Hausmann; E Palmer
Journal:  J Exp Med       Date:  1997-12-01       Impact factor: 14.307

5.  Physical dissociation of the TCR-CD3 complex accompanies receptor ligation.

Authors:  H Kishimoto; R T Kubo; H Yorifuji; T Nakayama; Y Asano; T Tada
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

6.  T cell receptor (TCR) antagonism without a negative signal: evidence from T cell hybridomas expressing two independent TCRs.

Authors:  S H Stotz; L Bolliger; F R Carbone; E Palmer
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

7.  Specific inflammatory osteoclast precursors induced during chronic inflammation give rise to highly active osteoclasts associated with inflammatory bone loss.

Authors:  Yaron Meirow; Milena Jovanovic; Yuval Zur; Juliana Habib; Daniele Filippo Colombo; Nira Twaik; Hadas Ashkenazi-Preiser; Kerem Ben-Meir; Ivan Mikula; Or Reuven; Guy Kariv; Leonor Daniel; Saja Baraghithy; Yehuda Klein; Jeroen Krijgsveld; Noam Levaot; Michal Baniyash
Journal:  Bone Res       Date:  2022-04-08       Impact factor: 13.567

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.